glp 1 plateau Study Aims to Break GLP-1 Weight-Loss Plateaus The GLP-1 Plateau Breakthrough Playbook

While this is rare with GLP-1s, if it occurs, please seek in-person care immediately

SDP has received research funding from AstraZeneca, Boehringer Ingelheim, Novartis Pharmaceuticals Co., and Merck Sharpe & Dohme, and is a consultant for or has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuticals, Laboratoires Servier, Merck Sharp & Dohme, Novartis Pharmaceuticals Co., Novo Nordisk, Sanofi, and Takeda

GLP-1 analogues, including semaglutide, have been instrumental in managing type 2 diabetes

The trial was registered with ClinicalTrials.gov (NCT02770885)